Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Times Interest Earned (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Times Interest Earned for 10 consecutive years, with -$11.26 as the latest value for Q3 2025.

  • On a quarterly basis, Times Interest Earned changed N/A to -$11.26 in Q3 2025 year-over-year; TTM through Sep 2025 was -$13.01, a 47.35% increase, with the full-year FY2024 number at -$3.61, up 81.9% from a year prior.
  • Times Interest Earned was -$11.26 for Q3 2025 at Theravance Biopharma, down from -$4.11 in the prior quarter.
  • In the past five years, Times Interest Earned ranged from a high of -$2.26 in Q2 2022 to a low of -$45.29 in Q1 2023.
  • A 5-year average of -$16.64 and a median of -$14.38 in 2023 define the central range for Times Interest Earned.
  • Peak YoY movement for Times Interest Earned: tumbled 279.16% in 2021, then soared 83.15% in 2025.
  • Theravance Biopharma's Times Interest Earned stood at -$25.1 in 2021, then fell by 26.27% to -$31.69 in 2022, then soared by 54.62% to -$14.38 in 2023, then increased by 0.53% to -$14.31 in 2024, then increased by 21.28% to -$11.26 in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Times Interest Earned are -$11.26 (Q3 2025), -$4.11 (Q2 2025), and -$22.45 (Q1 2025).